Viking Therapeutics, Inc.'s Phase 2 oral obesity drug data disappointed, showing high discontinuation rates and no clear efficacy or tolerability edge versus competitors. Viking’s lead candidate, ...
The MarketWatch News Department was not involved in the creation of this content. Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau ...
The safety and tolerability data were at odds with an earlier phase 1 trial, and not as good as a comparable drug trial result from Eli Lilly. Viking may decide to take VK2735 (oral form) through ...
Hosted on MSN
Viking Therapeutics outlines dual Phase III obesity programs while advancing oral VK2735 and maintenance regimens
Brian Lian, President and CEO, highlighted several milestones in 2025, focusing on the obesity pipeline: "With the subcutaneous formulation of our lead molecule, VK2735, following the positive ...
SAN DIEGO, Nov. 19, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine ...
GLP-1 market growth is fueling Viking Therapeutics‘ (VKTX) momentum with VK2735 in Phase 3 and VK2809’s NASH success. Viking is advancing dual therapies amid a $150 billion obesity opportunity. With a ...
(RTTNews) - Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, reported its fourth-quarter and full-year 2025 financial results ...
Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH Phase 3 Registrational Program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results